Title:
RECOMBINANT PROTEIN TARGETING PD-1 AND TGFβ
Document Type and Number:
WIPO Patent Application WO/2021/078123
Kind Code:
A1
Abstract:
A recombinant fusion protein comprising 1) TGFβR2, or a fragment thereof, capable of binding to TGFβ, and 2) an antibody, or an antigen-binding fragment thereof, that binds to PD-1. Also disclosed are a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of TGFβ and/or PD-1 using the recombinant protein.
Inventors:
KANG XIAOQIANG (CN)
HUANG XIAO (CN)
HUANG XIAO (CN)
Application Number:
PCT/CN2020/122242
Publication Date:
April 29, 2021
Filing Date:
October 20, 2020
Export Citation:
Assignee:
NANJING LEADS BIOLABS CO LTD (CN)
International Classes:
C07K19/00; A61K39/395; A61P35/00; C07K16/28; C12N15/63
Domestic Patent References:
| WO2020014285A2 | 2020-01-16 | |||
| WO2016161410A2 | 2016-10-06 |
Other References:
KARIN M. KNUDSON, KRISTIN C. HICKS, XIAOLING LUO, JIN-QIU CHEN, JEFFREY SCHLOM, SOFIA R. GAMEIRO: "M7824，a novel bifunctional anti-PD-L1/TGF beta Trap fusion protein， promotes anti-tumor efficacy as monotherapy and in combination with vaccine", ONCOIMMUNOLOGY, vol. 7, no. 5, e1426519, 4 May 2018 (2018-05-04), pages 1 - 14, XP055665440, ISSN: 2162-402X, DOI: 10.1080/2162402X.2018.1426519
See also references of EP 4048704A4
See also references of EP 4048704A4
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: